Is ADC Therapeutics SA (ADCT) overvalued? · rev $70.8M
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
This page asks whether ADC Therapeutics SA (ADCT) looks expensive on cached numbers — not a short thesis.
Latest reported ADCT revenue for 2024-12-31 was $70.8M. Net income was -$157.8M. Revenue was up 1.8% from 2023-12-31 to 2024-12-31. ADCT currently screens at market cap $141.2M.
ADCT currently screens at market cap $141.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ADCT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ADCT stock page for the full model, not this heading.
Not investment advice.